Island Pharmaceuticals Limited (ILA.AX)
- Previous Close
0.1800 - Open
0.1800 - Bid 0.1750 x --
- Ask 0.1800 x --
- Day's Range
0.1800 - 0.1800 - 52 Week Range
0.0580 - 0.2800 - Volume
52,857 - Avg. Volume
146,422 - Market Cap (intraday)
37.847M - Beta (5Y Monthly) 0.00
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0300 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.39
Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections in Australia and the United States of America. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. The company has a collaboration agreement with Monash University and National Cancer Institute IND. It also has a cooperative research and development agreement with the U.S. Army, Island in preparation for its Phase 2a/b clinical study for ISLA-101. Island Pharmaceuticals Limited was founded in 2017 and is based in Camberwell, Australia.
www.islandpharmaceuticals.comRecent News: ILA.AX
View MorePerformance Overview: ILA.AX
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ILA.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ILA.AX
View MoreValuation Measures
Market Cap
37.85M
Enterprise Value
36.61M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
9.73
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-65.80%
Return on Equity (ttm)
-143.22%
Revenue (ttm)
399.37k
Net Income Avi to Common (ttm)
-3.24M
Diluted EPS (ttm)
-0.0300
Balance Sheet and Cash Flow
Total Cash (mrq)
3.99M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-1.71M